Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia

NCT02267863 is registered in ClinicalTrials.gov with Aptose Biosciences Inc. as lead sponsor.

NCT NCT02267863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02267863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Lead sponsor
Aptose Biosciences Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2014
Completion date
September 30, 2021
Enrollment
21 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, acute myelogenous leukemia in relapse, acute myelogenous leukemia, adult, acute myelogenous leukemia, relapsed, adult, high risk myelodysplasia